Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › Mexichem Fluor S A De C V › 17577824
Last updated: May 29, 2026
Application No. 17/577,824

PHARMACEUTICAL COMPOSITION COMPRISING AN INDACATEROL COMPOUND, A PHARMACEUTICALLY ACCEPTABLE SALT OF GLYCOPYRROLATE AND 1,1-DIFLUOROETHANE

Non-Final OA
Filed
Jan 18, 2022
Priority
Sep 19, 2016 — GB 1615910.5 +3 more
Examiner
IVANOVA, SVETLANA M
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mexichem Fluor S A De C V
OA Round
3 (Non-Final)
50%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Interview Optional

— +51.9% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 50% grant rate with +51.9% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.
Based on 835 resolved cases, 2023–2026

Examiner Intelligence

IVANOVA, SVETLANA M View full profile →
Grants 50% of resolved cases
50%
Career Allowance Rate
422 granted / 835 resolved
-9.5% vs TC avg
Strong +52% interview lift
Without
With
+51.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
35 currently pending
Career history
866
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
60.2%
+20.2% vs TC avg
§102
7.9%
-32.1% vs TC avg
§112
14.1%
-25.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 835 resolved cases

Prosecution Timeline

Show 9 earlier events
Aug 06, 2025
Response after Non-Final Action
Aug 06, 2025
Notice of Allowance
Aug 26, 2025
Response after Non-Final Action
Jan 05, 2026
Request for Continued Examination
Jan 06, 2026
Response after Non-Final Action
Jan 23, 2026
Non-Final Rejection mailed
Mar 09, 2026
Examiner Interview Summary
Mar 09, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

18/479,338
Patent 12636367
PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND
2y 7m to grant Granted May 26, 2026
17/622,210
Patent 12624015
JNK INHIBITORS AS ANTICANCER AGENTS
4y 4m to grant Granted May 12, 2026
17/913,490
Patent 12616670
N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS
3y 7m to grant Granted May 05, 2026
18/374,215
Patent 12605385
METHOTREXATE FORMULATION
2y 6m to grant Granted Apr 21, 2026
17/758,839
Patent 12594248
STRESS MANAGEMENT IN HUMAN SUBJECTS IN NEED THEREOF
3y 8m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+51.9%)
2y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 835 resolved cases by this examiner. Grant probability derived from career allowance rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month